Relevant bibliographies by topics / Elocalcitolo

Contents

  1. Journal articles

Academic literature on the topic 'Elocalcitolo'

Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Elocalcitolo.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Elocalcitolo"

1

Morelli, Annamaria, Roberta Squecco, Paola Failli, et al. "The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder." American Journal of Physiology-Cell Physiology 294, no. 5 (2008): C1206—C1214. http://dx.doi.org/10.1152/ajpcell.90634.2007.

Full text
Abstract:
Human bladder contraction mainly depends on Ca2+ influx via L-type voltage-gated Ca2+ channels and on RhoA/Rho kinase contractile signaling, which is upregulated in overactive bladder (OAB). Elocalcitol is a vitamin D receptor agonist inhibiting RhoA/Rho kinase signaling in rat and human bladder. Since in the normal bladder from Sprague-Dawley rats elocalcitol treatment delayed the carbachol-induced contraction without changing maximal responsiveness and increased sensitivity to the L-type Ca2+ channel antagonist isradipine, we investigated whether elocalcitol upregulated L-type Ca2+ channels
APA, Harvard, Vancouver, ISO, and other styles
2

Borgogni, E., E. Sarchielli, M. Sottili, et al. "Elocalcitol Inhibits Inflammatory Responses in Human Thyroid Cells and T Cells." Endocrinology 149, no. 7 (2008): 3626–34. http://dx.doi.org/10.1210/en.2008-0078.

Full text
Abstract:
T-helper 1 (Th1) cell-mediated inflammatory responses predominate in the early pathogenesis of Graves’ disease (GD), whereas Th2 cell-mediated immunity may play a role in later stages. The chemokine CXCL10 and its receptor CXCR3 are expressed in most thyroid glands of early GD patients. Circulating CXCL10 levels inversely correlate with disease duration; CXCL10 maximal expression also correlates with interferon (IFN)γ levels in recent GD onset. Methimazole (MMI) reduces CXCL10 secretion by isolated thyrocytes, decreases serum CXCL10 levels, and promotes a transition from Th1 to Th2 dominance i
APA, Harvard, Vancouver, ISO, and other styles
3

Revill, P., N. Serradell, and J. Bolós. "Elocalcitol." Drugs of the Future 31, no. 12 (2006): 1042. http://dx.doi.org/10.1358/dof.2006.031.12.1060203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Elocalcitol beneficial for benign prostatic hyperplasia." Inpharma Weekly &NA;, no. 1610 (2007): 8. http://dx.doi.org/10.2165/00128413-200716100-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "BXL 628* [Elocalcitol] is effective in the treatment of overactive bladder,." Inpharma Weekly &NA;, no. 1538 (2006): 6. http://dx.doi.org/10.2165/00128413-200615380-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Streng, T., K. E. Andersson, P. Hedlund, et al. "548 ELOCALCITOL IMPROVES EFFECTS BY TOLTERODINE IN RATS WITH PARTIAL URETHRAL OBSTRUCTION." European Urology Supplements 10, no. 2 (2011): 181–82. http://dx.doi.org/10.1016/s1569-9056(11)60539-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Streng, Tomi, Karl-Erik Andersson, Petter Hedlund, et al. "Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction." BJU International 110, no. 2b (2012): E125—E131. http://dx.doi.org/10.1111/j.1464-410x.2011.10838.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tiwari, Atul. "Elocalcitol (BXL-628): a novel, investigational therapy for the therapeutic management of benign prostatic hyperplasia." Expert Opinion on Investigational Drugs 17, no. 5 (2008): 819–24. http://dx.doi.org/10.1517/13543784.17.5.819.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Adorini, Luciano, Giuseppe Penna, Susana Amuchastegui, et al. "Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol)." Journal of Steroid Biochemistry and Molecular Biology 103, no. 3-5 (2007): 689–93. http://dx.doi.org/10.1016/j.jsbmb.2006.12.065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Montorsi, Francesco, and Enrico Colli. "ELOCALCITOL IN THE TREATMENT OF BPH: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED PHASE IIB CLINICAL TRIAL." Journal of Urology 179, no. 4S (2008): 700–701. http://dx.doi.org/10.1016/s0022-5347(08)62043-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Elocalcitolo' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography